{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:07:21Z","timestamp":1784606841609,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Kanagawa Breast Oncology Group","award":["KBOG1301"],"award-info":[{"award-number":["KBOG1301"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.suronc.2020.10.002","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T11:25:47Z","timestamp":1601983547000},"page":"447-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-5001","authenticated-orcid":false,"given":"Kazutaka","family":"Narui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari S.","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-0648","authenticated-orcid":false,"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadatoshi","family":"Sugae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-7439","authenticated-orcid":false,"given":"Yoshimasa","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-6736","authenticated-orcid":false,"given":"Takuho","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-3317","authenticated-orcid":false,"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4641-2513","authenticated-orcid":false,"given":"Yutaka","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2020.10.002_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.suronc.2020.10.002_bib2","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.ejso.2019.08.001","article-title":"Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy","volume":"45","author":"Asaoka","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2020.10.002_bib3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.suronc.2020.10.002_bib4","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdu118","article-title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994\/BIG 1-00 phase III trial","volume":"25","author":"Bonnefoi","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.suronc.2020.10.002_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.breast.2018.04.018","article-title":"MRI and PET\/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis","volume":"40","author":"Li","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.suronc.2020.10.002_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1634\/theoncologist.2015-0353","article-title":"FDG-PET\/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy studies","volume":"21","author":"Sheikhbahaei","year":"2016","journal-title":"Oncol."},{"key":"10.1016\/j.suronc.2020.10.002_bib7","series-title":"AHRQ Comparative Effectiveness Reviews. Core Needle and Open Surgical Biopsy for Diagnosis of Breast Lesions: an Update to the 2009 Report","author":"Dahabreh","year":"2014"},{"key":"10.1016\/j.suronc.2020.10.002_bib8","series-title":"Breast Imaging Reporting and Data System\u00ae (BIRADS\u00ae). 4","author":"American College of Radiology","year":"2003"},{"key":"10.1016\/j.suronc.2020.10.002_bib9","series-title":"ACR BI-RADS\u00ae Atlas, Breast Imaging Reporting and Data System","article-title":"ACR BI-RADS\u00ae magnetic resonance imaging","author":"Morris","year":"2013"},{"key":"10.1016\/j.suronc.2020.10.002_bib10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.suronc.2020.10.002_bib11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","article-title":"A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann. Surg."},{"key":"10.1016\/j.suronc.2020.10.002_bib12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bjc.2015.381","article-title":"Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques","volume":"113","author":"Heil","year":"2015","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.suronc.2020.10.002_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.09.034","article-title":"Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?","volume":"69","author":"Heil","year":"2016","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.suronc.2020.10.002_bib14","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2214\/AJR.17.18323","article-title":"MRI, clinical examination, and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer: ACRIN 6657 trial","volume":"210","author":"Scheel","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.suronc.2020.10.002_bib15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jso.25663","article-title":"MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer","volume":"120","author":"Sener","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2020.10.002_bib16","first-page":"128","article-title":"Discrepancies between pathological tumor responses and estimations of complete response by magnetic resonance imaging after neoadjuvant chemotherapy differ by breast cancer subtype","volume":"18","author":"Namura","year":"2018","journal-title":"Clin. Breast Canc."},{"key":"10.1016\/j.suronc.2020.10.002_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1055\/s-2007-1022338","article-title":"Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy","volume":"54","author":"Sinn","year":"1994","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.suronc.2020.10.002_bib18","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.suronc.2020.10.002_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive Her2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.suronc.2020.10.002_bib20","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1245\/s10434-019-07741-w","article-title":"Validation of residual cancer burden as prognostic factor for breast cancer patients after neoadjuvant therapy","volume":"26","author":"Muller","year":"2019","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.suronc.2020.10.002_bib21","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1158\/1078-0432.CCR-19-0560","article-title":"Prognostic value of residual disease after neoadjuvant therapy in Her2-positive breast cancer evaluated by residual cancer burden, neoadjuvant response index, and neo-bioscore","volume":"25","author":"Steenbruggen","year":"2019","journal-title":"Clin. Canc. Res."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740420304102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740420304102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:22:10Z","timestamp":1760757730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740420304102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":21,"alternative-id":["S0960740420304102"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2020.10.002","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2020.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}